Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications.
Innovation in CNS
Enveric is advancing novel neuroplastogen therapeutics that have the potential to help millions of patients globally.
Development Pipeline
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
EB-003
Difficult-to-Treat Mental Health Disorders
Prescription Model
